Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Illumina

Illumina Stock Tumbles As Sales, Profits Decline — Why The First-Quarter Beat Has 'Mixed Implications'

DNA-sequencing leader Illumina eked out a first-quarter beat, but ILMN stock toppled Wednesday on its cloudy future.

Investors Business Daily

FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle

The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell on the news.

Investors Business Daily

Backlog in NHS genome service leaves families facing long wait for results

Exclusive: Experts say delays of more than a year risk children not getting relevant treatments or support

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Illumina Surges As Activist Investor Carl Icahn Attempts To Wrest Control

Activist investor Carl Icahn is fighting for control of Illumina after the acquisition of Grail. In response, ILMN stock surged Monday.

Investors Business Daily

Dow Jones Reverses On SVB Rescue Plan; First Republic, Charles Schwab Crash On Bank Fears

The Dow Jones fell Monday, as the FDIC guaranteed all deposits of SVB Financial. First Republic crashed 75% on ongoing bank fears.

Investors Business Daily

It takes an average of 8 years for a rare disease patient to get diagnosed. Why is it so hard to get life-altering genetic testing in the U.S.?

An increasingly inexpensive genetic test stands in the way of a diagnosis for many rare disease patients, who are as common as one in 10 worldwide.

Fortune

The Wild Card That Keeps Haunting DNA-Reading Giant Illumina

Illumina beat sales estimates, but profit came in light during the fourth quarter. That led ILMN stock to fall Wednesday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Cancer vaccines are already a reality—but your doctor might not tell you about them unless you ask

“Patients need to advocate for themselves."

Fortune

ChatGPT shows that the A.I. revolution has arrived. We’re not ready

Even more than social media, generative A.I. could disrupt business models and society itself. It's time to ask the tough questions.

Fortune

Illumina's Woes Mount As Guidance Lags And Grail Controversy Continues

Illumina stock plunged to its lowest point in three months Tuesday after the gene-sequencing giant issued a disappointing outlook for 2023.

Investors Business Daily

A frozen capital market and an insurance premium shock: 10 health care predictions for 2023 from top investors

Distressed deals, inflation in insurance premiums, and restrictions on transgender treatments. Here's what the health care sector will look like in 2023, according to top investors.

Fortune

Illumina Reverses Pitfall After Light Earnings Guidance On Quarterly Beat

Illumina stock surged Friday, reversing an after-hours decline Thursday, after the biggest genomics company issued a light earnings guide.

Investors Business Daily

Small wonder: big DNA advances loom at university startup Oxford Nanopore

Company spun out of Oxford University makes DNA and RNA sequencing devices to identify viruses and variants

The Guardian - UK

Looking At Illumina's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 26 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Upgrades

Axios

DNA sequencing is getting cheaper as competition in the industry heats up

Sequencing behemoth Illumina unveiled a new line of instruments today.

Benzinga

What Are Whales Doing With Illumina

Someone with a lot of money to spend has taken a bullish stance on Illumina (NASDAQ:ILMN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Former President Obama, Bill Gates headline Illumina's Genomics Forum next week in San Diego

Tailoring healthcare to an individual's genetics has long held the promise of transforming medicine. Next week, San Diego's Illumina hosts a check-up on the science and policy around precision health — with the help of some heavyweight speakers.

Tribune News Service

European regulators move to block Illumina's $7.1 billion acquisition of Grail

Europe's antitrust regulator on Tuesday moved to block San Diego's Illumina from acquiring Grail — one week after a U.S. administrative law judge found that the blockbuster $7.1 billion merger should be allowed to stand.

Investors Business Daily

Illumina Stock Pops After European Regulators Block $8 Billion Deal

Illumina stock jumped Tuesday after the EC blocked its acquisition of Grail — another step in a battle over the early cancer-detection outfit.

Benzinga

Top Financial Stories Tuesday, September 6: Focus on iPhone 14 Event, OPEC+ Plans Mild Production Cut, Netflix Says No To Crypto Ads And More…

Reuters EQT Corp Close To Buying THQ Appalachia

Benzinga

Illumina Whale Trades For September 02

A whale with a lot of money to spend has taken a noticeably bullish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 11 strange trades.

Benzinga

Top Financial Stories Friday, September 2: GM's Cruise Recalls Some Robotaxis Over Software Glitch, Chinese Tech Giant Suffers $43M Impairment Loss On Bitcoin and Ethereum Holdings And More..

Wall Street Journal

Benzinga

Dow, Nasdaq Futures Surge Ahead Of Jackson Hole Symposium

Pre-open movers

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.